Full Press Release Details
HIGH POINT, N.C., May 07, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development ofcadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that management will participate in the following investor conferences in May:
H.C. Wainwright 4th Annual BioConnect Investor ConferenceFormat: Fireside Chat & one-on-one investor meetingsDate: Tuesday, May 19, 2026Time: 12:30 PM ETLocation: New York, NYWebcast Link
Alliance Global Partners Healthcare Company ShowcaseFormat: Fireside ChatDate: Wednesday, May 20, 2026Time: 4:20 PM ETLocation: Virtual EventEvent Webcast Link
Live webcasts of the fireside chats will be available on the Media & Events section of the Company’s website at vtvtherapeutics.com. Replays of the webcasts will be available following the event.
AboutvTvTherapeuticsvTv Therapeutics is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. vTv’s clinical pipeline is led bycadisegliatin, currently in a U.S. Phase 3 trial, a potential first-in-class oral glucokinase activator being investigated for the treatment of type 1 diabetes. vTv and its development partners are investigating multiple molecules across different indications for chronic diseases. Learn more atvtvtherapeutics.comor follow the company onLinkedInorX.
About CadisegliatinCadisegliatin(TTP399) is a novel, oral small molecule, liver-selective glucokinase activator being investigated in the U.S. as a potential first-in-class oral adjunctive treatment for type 1 diabetes (T1D). In non-clinical studies,cadisegliatinacted selectively on the liver and increased glucokinase activity independently of insulin. These findings support clinical investigation of whethercadisegliatincan improve glycemic control through hepatic glucose uptake and glycogen storage.Cadisegliatinhas been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA).
Cadisegliatinis under investigation, and the safety and efficacy have not been established. There is no guarantee that this product will receive health authority approval or become commercially available for the use being investigated.